CTIS2023-503948-13-00招募中1 期
A Phase I study to evaluate the Pharmacokinetics and Safety of Letrozole LEBE in Healthy Post-menopausal Women.
aboratorios Farmaceuticos Rovi S.A.0 个研究点目标入组 90 人开始时间: 2023年3月22日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
A First-in-Human Study of a Controlled Release Formulation of Lanreotide acetate in healthy male volunteersNeuroendocrine TumoursMetabolic and Endocrine - Other endocrine disordersCancer - Neuroendocrine tumour (NET)AcromegalyACTRN12620001261909Ascil Australia Pty LTD16
已完成
1 期
A First-in-Human Study of a new Controlled Release Formulation of Octreotide acetate in healthy male volunteersNeuroendocrine TumoursMetabolic and Endocrine - Other endocrine disordersCancer - Neuroendocrine tumour (NET)AcromegalyACTRN12620000108910Ascil Australia Pty Ltd8
已完成
1 期
A Phase 1 Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Selgantolimod upon Co-administration with a Representative Proton Pump Inhibitor or H2-Receptor AntagonistHepatitis BOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonInfection - Other infectious diseasesACTRN12620001019998Gilead Sciences50
进行中（未招募）
不适用
Safety and Tolerability of Ceftazidime-Avibactam for pediatric patients with suspected or confirmed infectionshospitalized pediatric patients receiving systemic antibiotic therapy for suspected or confirmed infection.MedDRA version: 14.1Level: LLTClassification code 10021804Term: Infection bacterialSystem Organ Class: 100000004862EUCTR2013-001900-13-Outside-EU/EEAAstraZeneca AB32
已完成
1 期
A Phase 1 Study of AP02 (Nintedanib Solution for Inhalation) Delivered via the PARI eFlow®Nebulizer System in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis orProgressive Fibrosing Interstitial Lung DiseaseProgressive, Fibrosing Interstitial Lung DiseasesRespiratory - Other respiratory disorders / diseasesIdiopathic Pulmonary FibrosisACTRN12620001141932Avalyn Pharma Pty Ltd38